ClinicalTrials.gg
Active, not recruitingNCT04589650EPIK-P2Updated Oct 7, 2026Results posted

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

A Phase 2 interventional study of Alpelisib and Placebo in PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 36 sites in 12 countries. Open to participants aged 0 Days to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Oct 7, 2026Enrollment updated1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
0 Days to 100 Years
Sex
All
01

Study summary

This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

Read the detailed description

This is a Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and PK of alpelisib in pediatric and adult participants with PROS.

Study period 1 - Core Period: Double-blind treatment, with an upfront 16-week placebo-controlled period (From Randomization to the end of Week 24) - Groups 1 and 2 At study start, participants in Group 1 and Group 2 will be enrolled and randomized in a 2:1 ratio (104 participants in the active arms and 52 participants in the placebo arms) to alpelisib or matching placebo. The upfront placebo-controlled period will continue for the first 16 weeks. At the conclusion of week 16, those participants who were randomized to receive placebo will be switched to active treatment with alpelisib in a blinded fashion at the dose level received at the end of the placebo period. Those participants who were randomized to receive alpelisib, will continue their treatment at the same dose level.

During the initial 16 weeks of the Core period, study treatment will be given in a blinded fashion, starting from week 17 of the Core period in open label fashion. The randomized treatment assignment to the treatment arms will remain blinded to participants, Investigators and the study team until the time of the primary analysis, when the last participant reaches week 48 from randomization or discontinues earlier.

Study period 1 - Exploratory; Group 4, open label treatment with the alpelisib FCT formulation After the implementation of Global Protocol Amendment 01, approximately 6 participants 2 to 5 years of age will be enrolled in exploratory Group 4. These participants will receive alpelisib FCT in an open label setting.

Study period 2 - Extension 1: treatment with alpelisib (week 25 up to the end of week 48) - Groups 1 and 2 Participants (Group 1 and Group 2) will continue their treatment during this study period.

For Groups 1 and 2, dose escalation is NOT allowed during first 4 weeks of Extension 1 period (weeks 25-28).

Once a participant (Groups 1 and 2) has completed initial 24 weeks of study treatment and reached Week 29, dose escalation will be allowed (Refer to Section 6.5.1):

  • Group 1: Alpelisib (125mg, or 200mg, or 250 mg QD)
  • Group 2: Alpelisib (50mg, or 125mg, or 200mg, or 250 mg QD)

Study period 2 - Exploratory: Group 4, open label treatment with the alpelisib FCT formulation

For Group 4 dose escalation is allowed once participant has reached the age of 6 years old, has completed the initial 24 weeks of study treatment, and has reached week 25:

  • Group 4: Alpelisib (50 mg, or 125 mg, or 200 mg, or 250 mg QD)

Study period 3 - Extension 2: long-term treatment with alpelisib (Week 49 up to 5 years) - Groups 1 and 2 Groups 1 and 2 participants who continue the study until Week 48 and have clinical benefit from the study treatment, will enter a long-term extension period. Dose escalation and treatment beyond progression are allowed in both Group 1 and Group 2.

Study period 3 - Exploratory: Group 4, open label treatment with the alpelisib FCT formulation Group 4 participants who continue the study until Week 48 and have clinical benefit from the study treatment, will enter a long-term extension period. Dose escalation is allowed once a participant has reached the age of 6 years old, has completed the initial 24 weeks of study treatment, and has reached Week 25.

Exploratory study part: Group 3, open label treatment with the alpelisib granules formulation Group 3 will be an exploratory group of participants who are 0 to 5 years old and will receive the alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Group 3 will be open to enrollment only after implementation of Global Protocol Amendment 05. Dose escalation is allowed once a participant has reached the age of 6 years, has completed the initial 24 weeks of study treatment, and has reached Week 25.

Group 5 open-label treatment with the alpelisib FCT formulation:

Participants of Group 5 will be enrolled after implementation of Global Protocol Amendment 02 and immediately after enrollment of Group 2 has been completed and will receive a starting dose of 125 mg alpelisib FCT formulation once daily in an open-label setting.

Dose escalation is allowed for those who did not derive sufficient clinical benefit at the Investigator's discretion and once participant has reached at least Week 25.

Study period 4 - Extension 3: treatment with alpelisib (from Week 264 until last patient enrolled completes 5 years of treatment) All participants from all groups will be followed until the last patient enrolled completes 5 years of treatment or discontinues early, to collect additional safety of alpelisib and in order to ensure patient access to treatment in the absence of global commercial supply in pediatric and adult participants with PROS. Visits will be performed every 24 weeks and additional safety assessments every 48 weeks.

It is planned to enroll approximately 192 participants in total, 78 adults and 114 children and adolescents. A total of approximately 156 male or female participants (of age ≥ 6 years) with PROS will be randomized in a 2:1 ratio in Groups 1 and 2 (approximately 78 participants per age group). Additional exploratory groups (Group 3, Group 4 and Group 5) will include approximately a total of 36 participants (approximately 15 in Group 3, 6 in Group 4 and 15 in Group 5).

02

Conditions studied

  • PIK3CA-related Overgrowth Spectrum (PROS)

Keywords

  • PIK3CA-related overgrowth spectrum (PROS)
  • Alpelisib
  • BYL719
  • Adult
  • Pediatric
  • Phase II
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed and assent (when applicable) from the patient, parent, legal authorized representative, or guardian prior to any study-related screening procedures were performed.
  • Male or female patients age above 0 day at the time of informed consent: Group 1: ≥ 18 years old, Group 2: 6-17 years old, Group 3: ≥ 0-5 years old, Group 4: ≥ 2-5 years old, Group 5: 6-17 years old.
  • Patients with diagnosis of PROS with symptomatic and /or progressive overgrowth and at least one measurable PROS-related lesion confirmed by BIRC assessment who had syndromic disease or isolated features at the time of informed consent. Patients, who previously had been receiving systemic treatment for PROS, could enter the study.
  • Documented evidence of a somatic mutation(s) in the PIK3CA gene performed in local laboratories using a DNA-based test validated according to the local regulations at the time of informed consent.
  • A tissue sample (fresh or archival) was to be sent to a Novartis-designated central laboratory.
  • (in patients > 16 years old at study entry)/Lansky (≤ 16 years of age at study entry) performance status index ≥ 50.
  • Adequate bone marrow and organ function as assessed by central laboratory for eligibility.
  • Presence of at least one PROS-related defined as a lesion with longest diameter ≥ 2 cm, when the volume could be accurately and reproducibly measured by MRI, and associated with complaints, clinical symptoms or functional limitations affecting the patient's everyday life. Measurability was confirmed by BIRC before randomization.
  • Able to swallow study drug (as assessed within 7 days before study treatment start):
  • Groups 1, 2, 4, and 5: FCT, or as drinkable suspension when applicable.
  • Group 3: granules. Drug administration via feeding tube is allowed.

Key Exclusion Criteria:

  • Patient with only isolated macrodactyly, epidermal nevus/nevi and macroencephaly (the only clinical feature or a combination of any three of them), in absence of other PROS-related lesions at the time of informed consent.
  • Previous treatment with alpelisib and/or any other PI3K inhibitor(s).
  • Radiation exposure for PROS treatment purpose within the previous 12 months on those PROS areas, which were expected to qualify for target lesions (except lesion(s) progressing after completion of radiotherapy) at time of informed consent.
  • Debulking or other major surgery performed within 3 months at time of informed consent.
  • bleeding related to PROS: Grade 2 within 14 days or grade 3 and more within 28 days before study treatment start as per v4.03.
  • Clinically meaningful PROS-related thrombotic event (grade 2 and more as per CTCAE v4.03) within 30 days before informed consent, and/or sclerotherapy/embolization for vascular complications performed within 6 weeks before informed consent.
  • History of prior and or ongoing or ongoing investigations or treatment for malignancy at time of informed consent.
  • Clinically significant heart disease at time of informed consent.
  • Patients in Groups 1, 2, and 5 with documented pneumonitis or interstitial lung disease at time of informed consent and with impaired lung function (e.g., or DLCO ≤ 70% of predicted) that was not related to PROS. Patients in Groups 3 and 4 with documented or suspicious pneumonitis or interstitial lung disease based on MRI images at time of informed consent.
  • History of acute pancreatitis within 1 year before informed consent or past medical history of chronic pancreatitis at time of informed consent.
  • Patients with an established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus at time of informed consent.
  • Known impairment of gastrointestinal (GI) function due to concomitant GI disease that may significantly alter the absorption of the study drug at time of informed consent.
  • History of to any drugs or metabolites of PI3K inhibitor or any of the of alpelisib at time of informed consent.
  • Known history of Steven Johnson's syndrome, erythema multiforme or toxic epidermal necrolysis at time of informed consent.
  • Known history of seizure, or epilepsy, regardless of relatedness to PROS spectrum at time of informed consent, when epilepsy was not controlled and/or the patient may not be switched to non-enzyme inducing antiepileptic drug(s) at time of informed consent.
  • Patient with other concurrent severe and/or uncontrolled medical conditions that could, in the Treating Physician's judgment, contraindicate administration of alpelisib at time of informed consent. Patient with an active documented COVID-19 infection at time of informed consent could be included only when completely recovered and had no symptoms for at least 28 days before first dose of study medication.
  • Pregnant or breastfeeding female patients at time of informed consent.
  • Female patients of who did not consent to use a highly effective method of and male patients who did not consent to use a condom and/or a highly effective method of contraception for the duration of the study and for one week following discontinuation of alpelisib.
  • Patient was receiving any of the following medications and could not discontinue 7 days prior to the start of the treatment: strong inducers of or inhibitors of breast cancer resistance protein (BCRP).
  • Not able to understand and to comply with study instructions and requirements at time of informed consent.
  • Participation in a prior study within 4 weeks prior to study treatment start or within 5 half-lives of the investigational product, whichever was longer.
  • Patients with clinically significant worsening of PROS-related laboratory anomalies, physical signs and symptoms indicating an uncontrolled condition during the screening phase, particularly if systemic treatment with any other inhibitor of the PI3K/AKT/mTOR pathway was stopped prior to the start of study treatment. This included but was not limited to hypercoagulability state in patients not receiving prophylactic treatment.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    Adult cohort (group 1)- Alpelisib

    During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.

    Drug: Alpelisib

  • Placebo comparator
    Adult cohort (group 1)- Placebo

    During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.

    Drug: Alpelisib · Drug: Placebo

  • Experimental
    Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib

    During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.

    Drug: Alpelisib

  • Placebo comparator
    Pediatric cohort (group 2: 6 to 17 years old)-Placebo

    During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.

    Drug: Alpelisib · Drug: Placebo

  • Experimental
    Pediatric cohort (group 3: 0 to 5 years old)- Alpelisib granules

    Pediatric participants (0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose (\<1 month: 20 mg every other day; 1 to \<6 months: 20 mg daily; 6 to \<2 years: 40 mg daily; 2 to \<6 years: 50 mg daily).

    Drug: Alpelisib

  • Experimental
    Pediatric cohort (group 4: 2 to 5 years old)- Alpelisib FCT

    Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.

    Drug: Alpelisib

  • Experimental
    Pediatric cohort (group 5: 6-17 years old)-Alpelisib FCT

    Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.

    Drug: Alpelisib

Interventions

  • Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily.

    Also known as: BYL719

  • DrugPlacebo

    Participants will receive matching placebo once daily up to week 16.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 2

    A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC), provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non target lesions and without new lesions. Confirmation of response requires a subsequent imaging assessment performed at least 4 weeks after the onset of response. Participants who permanently discontinued alpelisib prior to confirmation of response, and participants who received surgery as rescue therapy prior to confirmation of response are considered as non-responders.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Key Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 2

    A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 16, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions. Participants who permanently discontinued alpelisib prior to Week 16, participants who received surgery as rescue therapy prior to Week 16, and participants who had a missing/non-evaluable radiological assessment at Week 16 are considered as non-responders.

    Time frame: Week 16

  2. Proportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 2

    A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 24, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions.

    Time frame: Week 24

  3. Frequency and Severity of Adverse Events in Groups 1 and 2 up to Week 16

    An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative). Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.

    Time frame: Up to Week 16

  4. Frequency and Severity of Adverse Events in All Groups of Participants Over Time

    Type, frequency, seriousness, and severity of treatment-emergent adverse events per CTCAE v4.03 criteria in participants with PROS over time.

    Time frame: Up to approximately 5 years

  5. Change From Baseline to Week 16 in Brief Pain Inventory (BPI) Worst Pain Intensity in Group 1 and 2

    For adult and pediatric patients 12 years of age and older, the BPI item that assesses worst pain intensity in the past 24 hours was used. Patients respond to the item on an 11-point response scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Worst pain intensity was averaged weekly over a 7-day period if a patient had completed the questionnaire for at least 4 days in the 7-day period. The weekly mean was calculated based on the available assessments. Clinically important change at Week 16 was defined as a 2-point reduction for patients who had a pain intensity score ≥ 4 at baseline. For patients with a baseline score \< 4, a 1-point reduction from baseline was also considered as a clinically important change.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  6. Number of Participants With Global Impression of Symptom Severity (PGIS) Score up to Week 16

    A Patient Global Impression of Symptom Severity item was used to understand the overall severity of symptoms experienced and clinical meaningfulness of treatment effects experienced during this study. This item included 5 response options: no symptoms, mild, moderate, severe, and very severe.

    Time frame: Week 4, Week 8, Week 16

  7. Percentage Change From Baseline in Target and MRI-measurable Non- Target Lesion Volume in Group 1 and Group 2

    Percentage change from baseline in the sum of target lesion volume, MRI-measurable non-target lesion volume and all MRI measurable (target an non-target) lesion volume as assessed by BIRC. Target lesions are defined as anatomically reproducibly defined tissue(s) masses, which may be composed of one or several tissue types, and can be accurately measured by imaging technique MRI. Target lesion(s) (up to 3) should be identified at screening, be at least 2 cm in the longest diameter at baseline (for each selected lesion) and may be further reproducibly assessed by MRI. MRI-measurable non-target lesions are defined as all anatomic lesions other than selected as target and may be measured at radiologic assessment (at least 2 cm in the longest diameter at baseline, the volume may be further reproducibly assessed by MRI).

    Time frame: From Baseline up to approximately 5 years

  8. Proportion of Participants With Changes From Baseline in Other Non-target Lesions in Group 1 and Group 2

    Percentage change from baseline in other non-target lesions (by BIRC). Non Target lesions are defined as: * Anatomic lesions, limb/trunkal areas affected by PROS, organomegaly when they may be measured only by caliper/ruler (e.g., circumference of changed limb or body part) * Truly non-measurable lesions (e.g., small lesions less than 2 cm on MRI, superficial visual lesions, masses, organomegaly, PROS-related enlargement of anatomic area identified by physical exam that is not measurable by reproducible imaging technique)

    Time frame: From Baseline up to approximately 5 years

  9. Proportion of Participants With New Lesions in Group 1 and Group 2

    The proportion of patients with new lesions (as assessed by BIRC) will be assessed throughout the study.

    Time frame: From Baseline up to approximately 5 years

  10. Pharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Maximum Concentration (Cmax)

    Maximum concentration of alpelisib following drug administration will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.

    Time frame: Week 17 Day 1 (Pre-dose, 1h post dose, 3h post dose, 5h post dose, 8h post dose , 24h post dose/ Pre-dose of Day 2), Week 20 Day 1 (Pre-dose, 3h post dose) and after Week 28, on Day 1 (Pre-dose and 3h post dose) 4 weeks after the first dose escalation

  11. Pharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Trough Concentration (Ctrough)

    The trough observed concentration of alpelisib will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.

    Time frame: Week 17 Day 1 (Pre-dose and 24 h post dose/ Pre-dose of Day 2), Week 20 Day 1 (Pre-dose) and after Week 28, on Day 1 (Pre-dose) 4 weeks after the first dose escalation

  12. Change From Baseline in Patient-reported Pain Assessed by Brief Pain Inventory (BPI) Worst Pain Intensity Item or Wong-Baker Faces Scale (Age Appropriate) in Pediatric and Adult Populations

    Change in scores from Brief Pain Inventory (BPI) items, or Wong-Baker Faces Scale (age appropriate). The BPI item that assesses worst pain intensity in the past 24 hours will be used to assess pain intensity for adult participants (≥18 years old) and pediatric participants (≥12 years old). Participants respond to the item on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). For children under 12, the Wong-Baker Faces Scale will be used in place of the BPI worst pain intensity item. This scale is a single-item that includes drawings of 6 faces that are associated with both a numeric rating and a descriptor (ranging from 0/no hurt - 10/hurts worst)

    Time frame: From Baseline up to approximately 5 years

  13. Changes From Baseline in Patient-reported Health-related Quality of Life Assessed by PROMIS-profile (Patient Reported Outcome Measurement Information System) in Pediatric and Adult Populations

    Change in scores from the PROMIS-profile (Patient Reported Outcome Measurement Information System). The PROMIS Profiles are a group of PROMIS short forms measuring different domains of health-related quality of life (physical function, fatigue, ability to participate in social/peer relationships, pain interference, pain severity, anxiety, depression and sleep disturbance). All items include 5 response options, except for the pain intensity item, which has 11 response options.

    Time frame: From Baseline up to approximately 5 years

  14. Changes From Baseline in Patient-reported Overall Impression of Symptoms Assessed by Patient Global Impression of Symptom Severity (PGIS) in Pediatric and Adult Populations

    Change in PGIS item. The PGIS is a single item to assess the participant's perception in the severity of their symptoms using a 5-point verbal rating scale, from "No symptoms" to "Very Severe".

    Time frame: From Baseline up to approximately 5 years

  15. Duration of Response (DOR) in Participants Who Received Alpelisib in Group 1 and Group 2

    Duration of response (DOR) is defined as the time from first documented response until progression of PROS lesions by BIRC or death.

    Time frame: From first documented response until progression of PROS lesions or death, assessed up to approximately 5 years

  16. Time to Treatment Failure in Participants Who Received Alpelisib in Group 1 and Group 2

    Time from randomization/alpelisib treatment start date until the discontinuation of study treatment due to lack of efficacy (including unsatisfactory therapeutic effect, disease progression) or safety reasons (including adverse events, death). Participants who complete the study or discontinue study treatment for other reasons (e.g. discontinuation due to Participant/Guardian decision, technical problems) will be censored at the date of last study treatment received.

    Time frame: From Baseline up to approximately 5 years

  17. Overall Clinical Response Rate as Assessed by Investigator in Participants Who Received Alpelisib in Group 1 and Group 2

    Proportion of participants with overall clinical response reported as improvement, stable or worsening of clinical condition, as assessed by the investigator

    Time frame: Week 16, 24, 40, 48, 72, 96 and thereafter every 48 weeks

  18. Proportion of Participants With Response During the Extension Period in Group 1 and Group 2

    Response (yes/no) at scheduled protocol visit. Response is defined by achieving at least 20% reduction from baseline in the sum of target lesion volumes (1 to 3 lesions, assessed by MRI by a blinded independent review committee (BIRC)), provided that none of the individual target lesions has ≥ 20% increase from baseline and in absence of progression of non-target lesions and without new lesions.

    Time frame: Week 40, 48, 72, 96, 144, 192, 240 and 264.

  19. Changes in Symptoms and Complications/Comorbidities up to Week 16 on Treatment With Alpelisib as Compared to Placebo in Group 1 and Group 2

    Change in PROS-related symptoms and complications/comorbidities associated with PROS up to Week 16 among participants with symptoms and complications/comorbidities present at baseline

    Time frame: Baseline up to Week 16

  20. Changes in Symptoms and Complications/Comorbidities Associated With PROS Over Time in Group 1 and Group 2

    Change in PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities present at baseline

    Time frame: Baseline up to approximately 5 years

  21. Proportion of Participants With Healthcare Visit/Hospitalized Due to PROS in Group 1 and Group 2

    Proportion of participants with healthcare visit/hospitalized due to PROS will be assessed for Group 1 and Group 2.

    Time frame: From Baseline up to approximately 5 years

  22. Proportion of Participants Requiring Rescue Surgery Due to PROS in Group 1 and Group 2

    Proportion of participants requiring rescue surgery due to PROS will be assessed for Group 1 and Group 2.

    Time frame: From Baseline up to approximately 5 years

07

Results

Posted Feb 10, 2025

Participant flow

The study is conducted globally across 12 countries. Recruitment in Group 3 will be open after protocol amendment 5 approval in 2025.

Participant flow — Overall Study
MilestoneGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo ArmExploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCTExploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCT
Started54275628716
Completed core52265526713
Completed extension 14624552674
Full analysis set (fas)54275628716
Full analysis set (fas) - byl71954056000
Safety set54275628716
Pharmacokinetic analysis set (pas)51255626716
Completed42235325715
Not completed1243301
Withdrew: Subject decision622000
Withdrew: Adverse event311101
Withdrew: Physician decision110000
Withdrew: Unsatisfactory therapeutic effect200000
Withdrew: Death000100
Withdrew: Guardian decision000100

Outcome measures

PrimaryProportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 2

A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC), provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non target lesions and without new lesions. Confirmation of response requires a subsequent imaging assessment performed at least 4 weeks after the onset of response. Participants who permanently discontinued alpelisib prior to confirmation of response, and participants who received surgery as rescue therapy prior to confirmation of response are considered as non-responders.

Time frame:
Up to 48 weeks
Reported as:
Number · % of confirmed responder by BIRC
Proportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 2
% of confirmed responder by BIRCGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Alpelisib Arm
Proportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 216.7 (7.0 to 31.1)23.2 (11.9 to 38.3)
SecondaryKey Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 2

A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 16, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions. Participants who permanently discontinued alpelisib prior to Week 16, participants who received surgery as rescue therapy prior to Week 16, and participants who had a missing/non-evaluable radiological assessment at Week 16 are considered as non-responders.

Time frame:
Week 16
Reported as:
Number · % of responder by BIRC
Key Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 2
% of responder by BIRCGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo Arm
Key Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 211.1 (4.2 to 22.6)0 (0.0 to 12.8)8.9 (3.0 to 19.6)0 (0.0 to 12.3)
SecondaryProportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 2

A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 24, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions.

Time frame:
Week 24
Reported as:
Number · % of confirmed responder by BIRC
Proportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 2
% of confirmed responder by BIRCGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Alpelisib Arm
Proportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 216.7 (7 to 31.1)19.6 (9.2 to 34.3)
SecondaryFrequency and Severity of Adverse Events in Groups 1 and 2 up to Week 16

An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative). Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Frequency and Severity of Adverse Events in Groups 1 and 2 up to Week 16
ParticipantsGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo Arm
Adverse Events (AEs)50265024
Treatment-related AEs3112199
AEs with grade >=311572
Treatment-related AEs with grade >=35130
Serious Adverse Events (SAEs)5232
Treatment-related SAEs3010
AEs leading to discontinuation1000
Treatment-related AEs leading to discontinuation1000
AEs leading to dose adjustment/interruption6644
AEs leading to dose reduction0000
AEs leading to dose interruption6644
AEs requiring additional therapy37194315
SecondaryFrequency and Severity of Adverse Events in All Groups of Participants Over Time

Type, frequency, seriousness, and severity of treatment-emergent adverse events per CTCAE v4.03 criteria in participants with PROS over time.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryChange From Baseline to Week 16 in Brief Pain Inventory (BPI) Worst Pain Intensity in Group 1 and 2

For adult and pediatric patients 12 years of age and older, the BPI item that assesses worst pain intensity in the past 24 hours was used. Patients respond to the item on an 11-point response scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Worst pain intensity was averaged weekly over a 7-day period if a patient had completed the questionnaire for at least 4 days in the 7-day period. The weekly mean was calculated based on the available assessments. Clinically important change at Week 16 was defined as a 2-point reduction for patients who had a pain intensity score ≥ 4 at baseline. For patients with a baseline score \< 4, a 1-point reduction from baseline was also considered as a clinically important change.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16
Reported as:
Mean · Score on a scale
Change From Baseline to Week 16 in Brief Pain Inventory (BPI) Worst Pain Intensity in Group 1 and 2
Score on a scaleGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo Arm
Change from BL at Week 4-0.9 ± 1.87-0.2 ± 1.540.2 ± 0.730.3 ± 0.82
Change from BL at Week 8-1.2 ± 2.13-0.7 ± 1.43-0.3 ± 0.910.1 ± 0.69
Change from BL at Week 12-0.9 ± 2.55-0.8 ± 1.41-0.4 ± 1.010.4 ± 0.62
Change from BL at Week 16-1.3 ± 2.46-0.1 ± 1.49-0.4 ± 1.340.3 ± 1.14
SecondaryNumber of Participants With Global Impression of Symptom Severity (PGIS) Score up to Week 16

A Patient Global Impression of Symptom Severity item was used to understand the overall severity of symptoms experienced and clinical meaningfulness of treatment effects experienced during this study. This item included 5 response options: no symptoms, mild, moderate, severe, and very severe.

Time frame:
Week 4, Week 8, Week 16
Reported as:
Count of participants · Participants
Number of Participants With Global Impression of Symptom Severity (PGIS) Score up to Week 16
ParticipantsGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo Arm
Week 4 — No symptoms129153
Week 4 — Mild20563
Week 4 — Moderate141042
Week 4 — Severe6200
Week 4 — Very severe1000
Week 8 — No symptoms127173
Week 8 — Mild20662
Week 8 — Moderate111043
Week 8 — Severe7110
Week 8 — Very severe0200
Week 16 — No symptoms158182
Week 16 — Mild14664
Week 16 — Moderate15721
Week 16 — Severe6500
Week 16 — Very severe1000
SecondaryPercentage Change From Baseline in Target and MRI-measurable Non- Target Lesion Volume in Group 1 and Group 2

Percentage change from baseline in the sum of target lesion volume, MRI-measurable non-target lesion volume and all MRI measurable (target an non-target) lesion volume as assessed by BIRC. Target lesions are defined as anatomically reproducibly defined tissue(s) masses, which may be composed of one or several tissue types, and can be accurately measured by imaging technique MRI. Target lesion(s) (up to 3) should be identified at screening, be at least 2 cm in the longest diameter at baseline (for each selected lesion) and may be further reproducibly assessed by MRI. MRI-measurable non-target lesions are defined as all anatomic lesions other than selected as target and may be measured at radiologic assessment (at least 2 cm in the longest diameter at baseline, the volume may be further reproducibly assessed by MRI).

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryProportion of Participants With Changes From Baseline in Other Non-target Lesions in Group 1 and Group 2

Percentage change from baseline in other non-target lesions (by BIRC). Non Target lesions are defined as: * Anatomic lesions, limb/trunkal areas affected by PROS, organomegaly when they may be measured only by caliper/ruler (e.g., circumference of changed limb or body part) * Truly non-measurable lesions (e.g., small lesions less than 2 cm on MRI, superficial visual lesions, masses, organomegaly, PROS-related enlargement of anatomic area identified by physical exam that is not measurable by reproducible imaging technique)

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryProportion of Participants With New Lesions in Group 1 and Group 2

The proportion of patients with new lesions (as assessed by BIRC) will be assessed throughout the study.

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryPharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Maximum Concentration (Cmax)

Maximum concentration of alpelisib following drug administration will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.

Time frame:
Week 17 Day 1 (Pre-dose, 1h post dose, 3h post dose, 5h post dose, 8h post dose , 24h post dose/ Pre-dose of Day 2), Week 20 Day 1 (Pre-dose, 3h post dose) and after Week 28, on Day 1 (Pre-dose and 3h post dose) 4 weeks after the first dose escalation

Results for this outcome have not been posted.

SecondaryPharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Trough Concentration (Ctrough)

The trough observed concentration of alpelisib will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.

Time frame:
Week 17 Day 1 (Pre-dose and 24 h post dose/ Pre-dose of Day 2), Week 20 Day 1 (Pre-dose) and after Week 28, on Day 1 (Pre-dose) 4 weeks after the first dose escalation

Results for this outcome have not been posted.

SecondaryChange From Baseline in Patient-reported Pain Assessed by Brief Pain Inventory (BPI) Worst Pain Intensity Item or Wong-Baker Faces Scale (Age Appropriate) in Pediatric and Adult Populations

Change in scores from Brief Pain Inventory (BPI) items, or Wong-Baker Faces Scale (age appropriate). The BPI item that assesses worst pain intensity in the past 24 hours will be used to assess pain intensity for adult participants (≥18 years old) and pediatric participants (≥12 years old). Participants respond to the item on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). For children under 12, the Wong-Baker Faces Scale will be used in place of the BPI worst pain intensity item. This scale is a single-item that includes drawings of 6 faces that are associated with both a numeric rating and a descriptor (ranging from 0/no hurt - 10/hurts worst)

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryChanges From Baseline in Patient-reported Health-related Quality of Life Assessed by PROMIS-profile (Patient Reported Outcome Measurement Information System) in Pediatric and Adult Populations

Change in scores from the PROMIS-profile (Patient Reported Outcome Measurement Information System). The PROMIS Profiles are a group of PROMIS short forms measuring different domains of health-related quality of life (physical function, fatigue, ability to participate in social/peer relationships, pain interference, pain severity, anxiety, depression and sleep disturbance). All items include 5 response options, except for the pain intensity item, which has 11 response options.

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryChanges From Baseline in Patient-reported Overall Impression of Symptoms Assessed by Patient Global Impression of Symptom Severity (PGIS) in Pediatric and Adult Populations

Change in PGIS item. The PGIS is a single item to assess the participant's perception in the severity of their symptoms using a 5-point verbal rating scale, from "No symptoms" to "Very Severe".

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) in Participants Who Received Alpelisib in Group 1 and Group 2

Duration of response (DOR) is defined as the time from first documented response until progression of PROS lesions by BIRC or death.

Time frame:
From first documented response until progression of PROS lesions or death, assessed up to approximately 5 years

Results for this outcome have not been posted.

SecondaryTime to Treatment Failure in Participants Who Received Alpelisib in Group 1 and Group 2

Time from randomization/alpelisib treatment start date until the discontinuation of study treatment due to lack of efficacy (including unsatisfactory therapeutic effect, disease progression) or safety reasons (including adverse events, death). Participants who complete the study or discontinue study treatment for other reasons (e.g. discontinuation due to Participant/Guardian decision, technical problems) will be censored at the date of last study treatment received.

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryOverall Clinical Response Rate as Assessed by Investigator in Participants Who Received Alpelisib in Group 1 and Group 2

Proportion of participants with overall clinical response reported as improvement, stable or worsening of clinical condition, as assessed by the investigator

Time frame:
Week 16, 24, 40, 48, 72, 96 and thereafter every 48 weeks

Results for this outcome have not been posted.

SecondaryProportion of Participants With Response During the Extension Period in Group 1 and Group 2

Response (yes/no) at scheduled protocol visit. Response is defined by achieving at least 20% reduction from baseline in the sum of target lesion volumes (1 to 3 lesions, assessed by MRI by a blinded independent review committee (BIRC)), provided that none of the individual target lesions has ≥ 20% increase from baseline and in absence of progression of non-target lesions and without new lesions.

Time frame:
Week 40, 48, 72, 96, 144, 192, 240 and 264.

Results for this outcome have not been posted.

SecondaryChanges in Symptoms and Complications/Comorbidities up to Week 16 on Treatment With Alpelisib as Compared to Placebo in Group 1 and Group 2

Change in PROS-related symptoms and complications/comorbidities associated with PROS up to Week 16 among participants with symptoms and complications/comorbidities present at baseline

Time frame:
Baseline up to Week 16

Results for this outcome have not been posted.

SecondaryChanges in Symptoms and Complications/Comorbidities Associated With PROS Over Time in Group 1 and Group 2

Change in PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities present at baseline

Time frame:
Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryProportion of Participants With Healthcare Visit/Hospitalized Due to PROS in Group 1 and Group 2

Proportion of participants with healthcare visit/hospitalized due to PROS will be assessed for Group 1 and Group 2.

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

SecondaryProportion of Participants Requiring Rescue Surgery Due to PROS in Group 1 and Group 2

Proportion of participants requiring rescue surgery due to PROS will be assessed for Group 1 and Group 2.

Time frame:
From Baseline up to approximately 5 years

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study treatment up to the cut-off date for the interim analysis (20-Mar-2024), approximately 35 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm0/54 (0%)5/54 (9.3%)47/54 (87%)
Group 1 (Greater or Equal to 18 Years) - Placebo Arm0/27 (0%)2/27 (7.4%)24/27 (88.9%)
Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Alpelisib Arm0/54 (0%)16/54 (29.6%)52/54 (96.3%)
Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Placebo Arm0/26 (0%)3/26 (11.5%)26/26 (100%)
Group 1 (Greater or Equal to 18 Years) All Adults in Alpelisib Period0/80 (0%)19/80 (23.8%)78/80 (97.5%)
Group 2 (6-17 Years) - Alpelisib Arm0/56 (0%)3/56 (5.4%)45/56 (80.4%)
Group 2 (6-17 Years) - Placebo Arm1/28 (3.6%)2/28 (7.1%)21/28 (75%)
Group 2 (6-17 Years) Alpelisib Period Alpelisib Arm0/56 (0%)8/56 (14.3%)53/56 (94.6%)
Group 2 (6-17 Years) Alpelisib Period Placebo Arm0/26 (0%)2/26 (7.7%)23/26 (88.5%)
Group 2 (6-17 Years) All Pediatrics in Alpelisib Period0/82 (0%)10/82 (12.2%)76/82 (92.7%)
Group 4 (2-5 Years) All Pediatrics0/7 (0%)3/7 (42.9%)7/7 (100%)
Group 5 (6-17 Years) All Pediatrics0/16 (0%)2/16 (12.5%)14/16 (87.5%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 1 (Greater or Equal to 18 Years) Alpelisib Period/Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) Alpelisib Period/Placebo ArmGroup 1 (Greater or Equal to 18 Years) All Adults in Alpelisib PeriodGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo ArmGroup 2 (6-17 Years) Alpelisib Period Alpelisib ArmGroup 2 (6-17 Years) Alpelisib Period Placebo ArmGroup 2 (6-17 Years) All Pediatrics in Alpelisib PeriodGroup 4 (2-5 Years) All PediatricsGroup 5 (6-17 Years) All Pediatrics
PneumoniaInfections and infestations0/540/272/540/262/800/560/280/560/260/822/71/16
IntussusceptionGastrointestinal disorders0/540/270/540/260/800/560/280/560/260/821/70/16
Staphylococcal infectionInfections and infestations0/540/270/540/260/800/560/280/560/260/820/71/16
CellulitisInfections and infestations1/541/271/541/262/800/560/281/561/262/820/70/16
ErysipelasInfections and infestations0/541/272/541/263/800/560/280/560/260/820/70/16
Diabetic ketoacidosisMetabolism and nutrition disorders0/540/270/541/261/800/560/280/560/260/820/70/16
Musculoskeletal painMusculoskeletal and connective tissue disorders0/540/270/540/260/800/560/280/561/261/820/70/16
Suicide attemptPsychiatric disorders0/540/270/541/261/800/560/280/560/260/820/70/16
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/540/270/541/261/800/560/280/560/260/820/70/16
Abdominal painGastrointestinal disorders1/540/272/540/262/800/560/280/560/260/820/70/16
Most frequent other events
Showing 10 of 137
Most frequent other events
EventGroup 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 1 (Greater or Equal to 18 Years) Alpelisib Period/Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) Alpelisib Period/Placebo ArmGroup 1 (Greater or Equal to 18 Years) All Adults in Alpelisib PeriodGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo ArmGroup 2 (6-17 Years) Alpelisib Period Alpelisib ArmGroup 2 (6-17 Years) Alpelisib Period Placebo ArmGroup 2 (6-17 Years) All Pediatrics in Alpelisib PeriodGroup 4 (2-5 Years) All PediatricsGroup 5 (6-17 Years) All Pediatrics
VomitingGastrointestinal disorders2/540/274/542/266/806/562/2810/567/2617/824/75/16
PyrexiaGeneral disorders5/540/278/542/2610/805/561/2817/568/2625/824/75/16
DiarrhoeaGastrointestinal disorders16/545/2721/548/2629/805/563/2815/566/2621/822/78/16
AlopeciaSkin and subcutaneous tissue disorders11/541/2721/544/2625/801/560/286/562/268/821/73/16
HeadacheNervous system disorders10/544/2716/546/2622/8011/563/2820/565/2625/822/72/16
COVID-19Infections and infestations6/544/2717/543/2620/809/563/2813/562/2615/820/71/16
Decreased appetiteMetabolism and nutrition disorders6/541/276/544/2610/804/561/286/561/267/822/72/16
Abdominal painGastrointestinal disorders9/541/2713/543/2616/805/562/2814/567/2621/820/71/16
NasopharyngitisInfections and infestations5/541/2712/541/2613/804/564/289/567/2616/821/72/16
Pain in extremityMusculoskeletal and connective tissue disorders3/541/2710/543/2613/802/561/2813/564/2617/820/70/16

Baseline characteristics

Age, Customized
Age, Customized(Participants)Group 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo ArmExploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCTExploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCTTotal
Children, 2 - < 6 years0000707
Children, 6 - < 12 years00281901259
Adolescent, 12 - < 18 years002890441
18 - < 65 years5427000081
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo ArmExploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCTExploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCTTotal
Female341427123898
Male201329164890
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 (Greater or Equal to 18 Years) - Alpelisib ArmGroup 1 (Greater or Equal to 18 Years) - Placebo ArmGroup 2 (6-17 Years) - Alpelisib ArmGroup 2 (6-17 Years) - Placebo ArmExploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCTExploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCTTotal
American Indian or Alaska Native0000000
Asian631030224
Native Hawaiian or Other Pacific Islander0000000
Black or African American0110002
White48224225713157
More than one race0120003
Unknown or Not Reported0010012
08

Study locations

36 sites
  • UCSF Birthmarks and Vascular Center
    San Francisco, California 94158, United States
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
  • Washington Univ School Of Medicine
    St Louis, Missouri 63110, United States
  • Fink Childrens Ambulatory Care Ctr
    New York, New York 10016, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children s Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Cinn Children Hosp Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • CHOP Abramson Pediatric Resch Ctr
    Philadelphia, Pennsylvania 19104, United States
  • Unv of TX Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • Childrens Hospital and Regional Medical Center
    Seattle, Washington 98105, United States
  • Novartis Investigative Site
    Montreal, Quebec H2X 1R9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1C5, Canada
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Shanghai, 200011, China
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Tours, 37044, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Hamburg, 22149, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Roma, RM 00165, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Novartis Investigative Site
    Oslo, 0372, Norway
  • Novartis Investigative Site
    Esplugues, Barcelona 08950, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Zurich, 8032, Switzerland
  • Novartis Investigative Site
    West Midlands, Birmingham B4 6NH, United Kingdom
  • Novartis Investigative Site
    London, SW17 0QT, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Fujino A, Kuniyeda K, Nozaki T, Ozeki M, Ohyama T, Sato I, Kamibeppu K, Tanaka A, Uemura N, Kanmuri K, Nakamura K, Kobayashi F, Suenobu S, Nomura T, Hayashi A, Nagao M, Kato A, Aramaki-Hattori N, Imagawa K, Ishikawa K, Ochi J, Horiuchi S, Nagabukuro H. The Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome to Guide Designing a Proof-of-Concept Clinical Trial for Novel Therapeutic Intervention. Lymphat Res Biol. 2024 Feb;22(1):27-36. doi: 10.1089/lrb.2023.0023. Epub 2023 Dec 19. PubMed 38112724 ↗
  • Madsen RR, Semple RK. PIK3CA-related overgrowth: silver bullets from the cancer arsenal? Trends Mol Med. 2022 Apr;28(4):255-257. doi: 10.1016/j.molmed.2022.02.009. Epub 2022 Mar 8. PubMed 35272946 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Mar 2024, 35 months.

Results were first posted in Feb 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 19, 2020
StartActual
Apr 19, 2021
Primary completionActual
Mar 20, 2024
CompletionEst.
Jan 9, 2031
Results first posted
Feb 10, 2025
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University of North Carolina at Chapel Hill · Chapel Hill, United States
Show 1 removed
  • UNC Chapel Hill · Chapel Hill, United States
Oct 7, 2026
Enrollment
206→236
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    1 site added, 1 site removed
    Show site
    • University of North Carolina at Chapel Hill · Chapel Hill, United States
    Show 1 removed
    • UNC Chapel Hill · Chapel Hill, United States
    Enrollment 206→236
    + 2 other changes: verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04589650
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Apr 19, 2021
Primary completion
Mar 20, 2024
Completion
Jan 9, 2031 (estimated)
Results posted
Feb 10, 2025
Last update
Oct 7, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion